http://www.reportlinker.com/p092557/World-Imaging-Agents-(Contrast-Media-Radiopharmaceuticals)-Market.html

This report analyzes the worldwide markets for Imaging Agents in Millions of US$. The major product segments analyzed are Contrast Media (X-Ray, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 67 companies including many key and niche players worldwide such as AMAG Pharmaceuticals Inc., Amersham Plc, Bayer Schering Pharma AG, Bayer HealthCare Pharmaceuticals, Bracco Group, E-Z-EM Inc., Covidien, Cytogen Corp., Daiichi Sankyo Company Limited, Eisai Co., Ltd, EPIX Pharmaceutical Inc., Guerbet Group, and Lantheus Medical Imaging. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

IMAGING AGENTS MCP-3336
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
A. Contrast Media I-3
X-Ray Contrast Media I-3
Magnetic Resonance Imaging (MRI) Contrast Media I-3
Ultrasound Contrast Media I-4
B. Diagnostic Radiopharmaceuticals I-4
II. EXECUTIVE SUMMARY
1. Industry Overview II-1
A Quick Primer On Imaging Agents II-1
Growth Drivers II-1
Growth Inhibitors II-2
Changing Dynamics of Imaging Agents II-2
Imaging Agents: Significant Growth Ahead II-3
Table 1: Worldwide Imaging Agents Market (2003): Percentage
Breakdown of Value Sales for Leading Imaging
Agents-Omnipaque, Cardiolite, Magnevist, Iopamiron,
Ultravist, Myoview, Visipaque, Omniscan, FDG and Others
(includes corresponding Graph/Chart) II-4
Rise of Non-Ionizing Imaging Techniques II-4
Table 2: Medical Diagnostic Procedures Conducted Worldwide
for the Year 2003: Breakdown by Imaging Modality Type -
X-ray/CT, MRI, Ultrasound and Radiopharmaceuticals (In
Millions) (includes corresponding Graph/Chart) II-5
Fusion Imaging Modalities: Greater Clinical Benefits II-5
Radiopharmaceuticals-An Exotic Tool II-5
Nanomaterials Taking the Center Stage II-6
Gadolinium Coated Nanoparticles- A Promising Imaging Agent II-6
A Peek Into the Pricing Dynamics II-6
A Synoptic Overview II-6
Pros & Cons II-7
Positive Factors Driving Prices II-7
Negative Factors Bearing Down on Prices II-7
Reimbursements II-8
"Under the Umbrella" II-8
Europe II-8
United States II-8
2. Market Trends & Issues II-10
Falling Prices Turn On the Heat II-10
X-Ray Contrast Media: Declining Sector II-10
MRI Contrast Media: Playing at Center Court II-10
Impact Wielded by Ballooning MRI Practices II-10
Ultrasound Contrast Media: A Rising Star in the Quadrant II-11
Fledging Market Battles Teething Challenges II-12
PET: A Prime Growth Driver for Radiopharmaceuticals II-12
Nuclear Medicine: A Potential Growth Avenue for
Radiopharmaceuticals II-13
Select Cardiology and Oncology Radiopharmaceuticals II-13
3. Competition II-14
Market Structure II-14
Key Market Metrics II-15
Big Guns in the Emerging MRI Market II-15
Bayer Schering Pharma AG: A Pioneering Developer of MRI
Contrast Agents II-15
Competitive Scenario - A Recent Past Perspective II-16
Table 3: Worldwide Imaging Agents Market (2004): Percentage
Breakdown of Value Sales for Leading Players- GE Healthcare,
Bracco, Tyco Healthcare/Mallinckrodt, Schering, BMS and
Others (includes corresponding Graph/Chart) II-16
Table 4: X-ray Medical Diagnostics Market Worldwide:
Percentage Market Share of Leading Players for the Years
2002, 2003, and 2004 - Amersham, Bracco, Tyco/ Mallinckrodt,
Inc, Schering, Guerbet and Others (Revenue Share) (includes
corresponding Graph/Chart) II-16
Table 5: MRI Diagnostics Market Worldwide: Percentage Share
of Leading Players for the Years 2003 and 2004 - Schering,
Amersham, Bracco, and Others (Revenue Share) (includes
corresponding Graph/Chart) II-17
Table 6: Radiopharmaceutical Medical Diagnostics Market
Worldwide: Percentage Market Share of Leading Players for the
Years 2003 and 2004 - Amersham, Bristol-Myers Squibb, Tyco/
Mallinckrodt, Inc and Others (Revenue Share) (includes
corresponding Graph/Chart) II-17
4. Technology Breakthroughs II-18
Molecular Imaging Agents: The Outer Limits II-18
On Cards: Hyperpolarized Gases as Contrast Agents II-18
Imaging Agents Make a Welcome Impact in the Field of
Alzheimer's Disease II-18
Technetium-99m: A Breakthrough Contrast Agent for CNS Imaging II-19
A New Imaging Agent for Radiopharmaceutical Scans II-19
Multi-Modal Image Registration: Combating Contrast Medium
Inconsistencies II-19
Saline Flushes To Help Ensure Accurate Delivery of Contrast
Agents II-20
5. Product Overview II-21
Contrast Agents II-21
Contrast Media: How Do They Function? II-21
Where Are They Used ? II-22
Evolution of Contrast Media: A Profile II-22
Bismuth Nitrate: Beginning of Contrast Agents II-22
Imaging Agents: Significant Developments in the Last Fifty Years II-23
Schering Develops First Intravenous Contrast Agent II-23
MRI: Creating a New Era for Contrast Agents II-23
A Peek into the Finer Points of Differences Among Contrast Media II-23
Viscosity II-23
Osmolality II-23
Chemotoxicity II-24
Second Generation Non-Ionic Contrast Agents: An Introduction II-24
Choice of the Contrast Medium: A Weighty Decision II-24
Factors affecting choice of Imaging Agents II-24
Taxonomy II-24
Types of Contrast Media II-24
X-Ray Contrast Medium II-25
First Generation High Osmolar Contrast Media II-25
Second Generation Low Osmolar Contrast Media or LOCM II-25
Table 7: Comparative Analysis of Structure of Non-ionic
and ionic X-ray Contrast Media II-26
MRI Contrast Medium II-26
Role of Contrast Enhancement in MR Angiography (MRA) II-27
MRI Contrast Agents for the Liver II-27
Paramagnetic extracellular contrast agents II-27
Hepatobiliary Gadolinium Chelates II-27
Superparamagnetic Iron Oxide Particles II-28
Ultrasound Contrast Medium II-28
Ultrasonographic Contrast Media: What Are They? II-28
Ultrasound Contrast Enhancement in Cardiology II-29
Functionalities of Vascular Ultrasound Contrast Agents II-29
Diagnostic Radiopharmaceuticals II-30
Key Radioactive Isotopes used as Diagnostic
Radiopharmaceuticals II-30
A Delineate of Diagnostic Radiopharmaceuticals II-31
Diagnostic Radiopharmaceuticals: A Technical Run-Through II-31
Applications II-32
6. A Segmental Review II-33
Contrast Media II-33
Popular Brands of Contrast Agents Available Worldwide II-33
A Peek into Select Imaging Agents Under Clinical Trials
Worldwide II-35
X-ray Contrast Media II-35
Market Scenario II-35
MRI Contrast Media II-36
Market Scenario II-36
Ultrasound Contrast Media II-36
Market Overview II-36
Competitive Scenario II-36
Diagnostic Radiopharmaceuticals II-36
Market Overview II-36
Immunoconjugates II-37
Market Overview II-37
Competitive Scenario II-37
7. Technology Dynamics II-38
Proprietary Technologies Making Significant In-Roads II-38
Advanced Magnetics' Proprietary Colloidal Superparamagnetic
Particle Technology II-38
Enzon's Single Chain Antigen-Binding Technology II-38
Immunomedics' Antibody Technology II-38
First Generation II-38
Second Generation II-38
Third Generation II-38
NeoRx's "Painting the Target" Technology II-39
Stage - I II-39
Stage - II II-39
Stage - III II-39
Gas Encapsulation Technology for Ultrasound Contrast Media II-39
Pharmacyclics' Texaphyrin Technology II-40
Regulatory Bodies II-40
Ultrasound Contrast Agents Are Drugs, Not Devices - Rules US FDA II-40
Entry Barriers II-40
Research Driven Markets II-40
Highly Competitive Market II-40
Economies of Scale II-41
Substitutes in Agents Manufacturing II-41
New X-ray Diagnostic Agents II-41
Amide-based Macrocyclic Ligands - Potential MRI Agents II-41
Gadolinium (III) Complexes - Potential MRI Contrast Agents II-41
Metal-Containing Compounds Act As Potential Contrast Agents II-41
Therapeutic Applications II-41
Diagnostic Applications II-41
Magnetic Gels as Potential MRI Contrast Agents II-42
PFCs as Diagnostic Contrast Agents II-42
8. Product Launches II-43
Bayer to Unleash Radiology Management System II-43
Bayer to Unveil Pre-Filled Contrast-Medium Cartridges for MRI II-43
Insight Agents to Launch Generic Contrast Media Solutions In
Europe II-43
Researchers Develop First Biocompatible MRI Contrast Agent II-43
Signalomics and Invitrogen Collaborate to Develop Nanocrystal
Reagents II-43
Schering AG Collaborates with Stanford University to Develop
Molecular Imaging Agent II-44
Schering and Avid to Develop Diagnostic Imaging Agents II-44
US National Institutes of Health Develops two PET Imaging Agents II-44
Bracco Diagnostics Canada Introduces MRI Contrast Agent
MultiHance II-44
JBCPL Launches Magnilek Contrast Agent II-44
Mallinckrodt Launches NeutroSpec(TM) II-44
Schering AG's Primovist(TM) Approved in Sweden II-45
Isovue - A Non-ionic Monomeric X-Ray Contrast Agent from
Bracco Diagnostics II-45
Schering Strengthens Position with MS-325 II-45
Berlex Launches MRI Contrast Agent II-45
Amersham Health Introduces Omnipaque II-45
Boston Scientific Corp Launches Galaxy System II-46Syncor International Launches F-18 FDG II-46
9. Recent Industry Activity II-47
Bristol-Myers Squibb Medical Imaging Adopts New Identity,
Lantheus Medical Imaging II-47
Cytogen Corporation to Merge Business with EUSA Pharma Inc II-47
Bracco Group Acquires E-Z-EM II-47
EPIX Pharmaceuticals to Resubmit New Drug Application (NDA)
for Vasovist II-47
Bayer Schering, FutureChem Ink Licensing Deal II-47
NuView Radio Pharmaceuticals Inks Agreement for Non- Invasive
Imaging Agent II-48
Advanced Magnetics Inc Changes Name to AMAG Pharmaceuticals II-48
Bracco Diagnostics Inks Agreement with HealthTrust Purchasing
Group II-48
Bracco Diagnostics Offers MRI Products to HealthTrust
Purchasing Group II-48
Bayer HealthCare Offers MRI Contrast Agent to HealthTrust II-48
Bayer HealthCare Extends Contract with Premier II-48
Bayer HealthCare Sets Off US Operations II-49
Tyco Healthcare Renamed to Covidien Ltd II-49
Covidien Offers Imaging Solutions to MedAssets Supply Chain
Systems II-49
Siemens, M.D. Anderson Cancer Center Set up Research Centre II-49
Bayer, Berlex Merge Operations II-49
AION Diagnostics Forays Pre-Clinical Imaging Agent Market II-49
ART Acquires Alerion Biomedical II-50
EPIX to Merge with Predix II-50
Fujifilm Acquires Stake in Daiichi Radioisotope Laboratories II-50
Bracco Diagnostics Inks Agreement with Amerinet Vasovist
receives Green Signal in Australia II-50
AION Diagnostics Develops BioSilicon TM II-50
Sonazoid Receives Import Approval II-51
Schering AG Divests Radiopharmaceutical Business to Ion Beam
Applications and Institut National des Radioelements II-51
Vasovist Receives European Approval II-51
Albany Molecular Research Renews Supply Agreement with GE
Healthcare II-51
QuantRx Biomedical Corp. Acquires Stake in FluoroPharma II-51
Palatin Technologies Withdraws NeutroSpec Imaging Agent II-51
Diosynth Bags Contract to Produce Imaging Agent II-52
GE Healthcare Signs Marketing Agreement with PhotoCure II-52
DRAXIMAGE Receives the Green Signal in Europe II-52
Daiichi and Sankyo Sign a Merger Deal II-52
Bristol Myers and Imcor Pharmaceutical Forge Cross- Licensing
Agreement II-52
Kereos and Dow to Develop Unique Targeted Imaging Agents II-52
Bristol-Myers and Kereos to Collaborate on Molecular Imaging
Agents II-53
GE Acquires Amersham PLC II-53
Photogen Technologies Acquires Imagent(R) II-53
Dow and Kereos Collaborate II-53
IBC Pharmaceuticals and Schering AG Collaborate on Cancer
Research II-53
Schering Purchases CIS Bio International II-53
Imaging Diagnostic Systems to Collaborate with Schering II-54
Mallinckrodt Signs Distribution Agreement with Proxima
Therapeutics II-54
Immunomedics Signs Marketing Agreement with Teva-Tuteur II-54
DRAXIS Increases BrachySeed Production II-54
DRAXIMAGE Obtains FDA Approval for Manufacturing Lyophilized
Products II-55
Nycomed Amersham Acquires Bruker's TOMOJET II-55
DuPont Acquires Caribbean-PharmaLogic Radiopharmacies II-55
Bristol-Myers Squibb Company Acquires DuPont Pharmaceuticals II-55
Alliance Pharmaceutical Completes Acquisition of Molecular
Biosystems II-55
GE Medical Acquires Coincidence Technologies II-56
Tyco International Acquires Mallinckrodt II-56
Zydus Cadila Acquires 27.72 % Stake in German Remedies II-56
Schering Acquires Manufacturing Rights of MS-325 from EPIX
Medical II-56
Zydus Cadila Acquires Five Brands from Asta Medica II-56
AxCell BioSciences Forms Joint Venture with Institute for
Systems Biology II-56
Syncor Signs Purchasing Agreements with HSCA II-57
Syncor and InSource Health Services Sign Agreement II-57
DRAXIS Signs Agreement with BTG for INFECTON II-57
Peregrine Pharmaceuticals and Paul Scherrer Institute Expand
R&D Agreement II-57
Syncor and Broadlane Ink Agreement II-57
Syncor and Catholic Healthcare West Extend Agreement II-58
MedImmune and Targesome Sign R&D Agreement II-58
Vital Images Inks an Agreement with E-Z-EM Inc II-58
TriPath Imaging and MDS Ink Agreement II-58
North American Scientific Forges Strategic Relationship with
Certus International II-58
Mediaworks Launches RadiologyWeb II-59
Nycomed Amersham Extends Supply Contract with Novation II-59
Advanced Magnetics Receives Approval for Feridex II-59
Targesome Receives NCI Support for Developing Novel Diagnostic
Imaging Agents II-59
Bracco Acquires Product Lines and Intellectual Property of
Resolution Pharmaceuticals II-59
Guerbet Acquires Oxilan, an X-Ray Contrast Agent from Cook
Imaging II-60
Nycomed Amersham Imaging Associates with Global Healthcare
Exchange II-60
Nycomed Amersham and D-Pharm Ally to Develop New Imaging Agents II-60
Bracco Group Forges Strategic Alliance with Dyax Corp II-60
DRAXIS Signs Agreement with Cytogen Corp II-61
CV Therapeutics and Fujisawa Healthcare Sign Collaboration
Agreement II-61
Comprehensive Medical Imaging Signs Agreement with US Diagnostic II-61
Syncor International and GE Medical Systems Sign Strategic
Agreement II-61
Guilford Pharmaceuticals Licenses Dopascan to MAP Medical
Technologies II-62
Cytogen and Advanced Magnetics Sign Agreements II-62
Amersham Sells Nycomed Pharma Subsidiary II-62
Amersham Renames its Businesses II-62
Nycomed Amersham Obtains Approval from FDA for MYOVIEW II-62
Schering Obtains Approval for Cancer Imaging Agent II-62
Datscan Receives European Union Marketing Authorization II-63
10. Focus on Select Players II-64
AMAG Pharmaceuticals Inc (USA) II-64
Amersham Plc (UK) II-64
Bayer Schering Pharma AG (Germany) II-65
Bayer HealthCare Pharmaceuticals (US) II-65
Bracco Group (Italy) II-65
E-Z-EM Inc. (USA) II-66
Covidien (USA) II-66
Cytogen Corp. (USA) II-66
Daiichi Sankyo Company Limited (Japan) II-67
Eisai Co., Ltd (Japan) II-67
EPIX Pharmaceutical Inc. (USA) II-67
Guerbet Group (France) II-67
Lantheus Medical Imaging (USA) II-68
11. Global Market Perspective II-69
Table 8: World Recent Past, Current & Future Analysis for
Imaging Agents by Geographic Region- US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-69
Table 9: World Long-term Projections for Imaging Agents by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-70
Table 10: World 10-Year Perspective for Imaging Agents by
Geographic Region- Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Markets for Years 2003, 2008 &
2012 (includes corresponding Graph/Chart) II-71
Table 11: World Recent Past, Current & Future Analysis for
Contrast Media by Geographic Region- US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-72
Table 12: World Long-term Projections for Contrast Media by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-73
Table 13: World 10-Year Perspective for Contrast Media by
Geographic Region- Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Markets for Years 2003, 2008 &
2012 (includes corresponding Graph/Chart) II-74
Table 14: World Recent Past, Current & Future Analysis for
Contrast Media by Product Segment - X-Ray, MRI and Ultrasound
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-75
Table 15: World Long-term Projections for Contrast Media by
Product Segment - X-Ray, MRI and Ultrasound Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-75
Table 16: World 10-Year Perspective for Contrast Media by
Product Segment - Percentage Breakdown of Dollar Sales for
X-Ray, MRI and Ultrasound Markets for Years 2003, 2008 & 2012
(includes corresponding Graph/Chart) II-76
Table 17: World Recent Past, Current & Future Analysis for
X-Ray Contrast Media by Geographic Region- US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-77
Table 18: World Long-term Projections for X-Ray Contrast Media
by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-78
Table 19: World 10-Year Perspective for X-Ray Contrast Media
by Geographic Region- Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Markets for Years 2003, 2008 &
2012 (includes corresponding Graph/Chart) II-79
Table 20: World Recent Past, Current & Future Analysis for MRI
Contrast Media by Geographic Region- US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-80
Table 21: World Long-term Projections for MRI Contrast Media
by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), Middle East and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-81
Table 22: World 10-Year Perspective for MRI Contrast Media by
Geographic Region- Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Markets for Years 2003, 2008 &
2012 (includes corresponding Graph/Chart) II-82
Table 23: World Recent Past, Current & Future Analysis for
Ultrasound Contrast Media by Geographic Region- US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Middle East and
Latin America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-83
Table 24: World Long-term Projections for Ultrasound Contrast
Media by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Middle East and Latin America
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-84
Table 25: World 10-Year Perspective for Ultrasound Contrast
Media by Geographic Region- Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Middle East and Latin America Markets for Years 2003,
2008 & 2012 (includes corresponding Graph/Chart) II-85
Table 26: World Recent Past, Current & Future Analysis for
Diagnostic Radiopharmaceuticals by Geographic Region- US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle
East and Latin America Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-86
Table 27: World Long-term Projections for Diagnostic
Radiopharmaceuticals by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-87
Table 28: World 10-Year Perspective for Diagnostic
Radiopharmaceuticals by Geographic Region- Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Middle East and Latin America
Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) II-88
III. MARKET
1. The United States III-1
A.Market Analysis III-1
Outlook III-1
Growth Stimulants III-1
Medical Imaging: Changing the Healthcare Landscape III-1
Dynamics of Pricing III-1
Table 29: Hospital Purchases by GPOs in the United States -
Percentage Breakdown by Type for the Year 2002 (includes
corresponding Graph/Chart) III-2
Reimbursements Issues III-2
Medicare III-2
Magnetic Resonance Imaging III-3
Table 30: Medicare Reimbursements for Brain MRI Procedures
for the Year 2006 III-4
Table 31: Medicare Reimbursements for Breast MRI
Procedures for the Year 2006 III-5
Regulatory Environment III-5
Provisions Regarding Off-Label Usage of Contrast Media III-6
Contrast Media III-6
X-ray Contrast Media III-6
MRI Contrast Media III-7
Market Scenario III-7
Managed Care Vs MRI Technology Diffusion III-7
Ultrasound Contrast Media Market III-7
Diagnostic Radiopharmaceuticals III-7
Market Scenario III-7
Availability of Isotopes: A Tough Challenge III-7
Select Players III-8
Strategic Corporate Developments III-10
Product Launches III-20
B.Market Analytics III-22
Table 32: US Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment- Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-22
Table 33: US Long-term Projections for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-22
Table 34: US Historic Review for Imaging Agents by Product
Segment- Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
1995 through 1999 (includes corresponding Graph/Chart) III-23
Table 35: US 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-23
2. Canada III-24
A.Market Analysis III-24
Outlook III-24
Diagnostic Equipment Market III-24
LOCM Products Approved in Canada III-24
Select Player III-24
Strategic Corporate Developments III-25
B.Market Analytics III-27
Table 36: Canadian Recent Past, Current & Future Analysis
for Imaging Agents by Product Segment- Contrast Media
(X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) III-27
Table 37: Canadian Long-term Projections for Imaging Agents
by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-28
Table 38: Canadian 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-29
3. Japan III-30
A.Market Analysis III-30
Outlook III-30
Reimbursement Issues III-30
Select Players III-30
Strategic Corporate Developments III-31
B.Market Analytics III-32
Table 39: Japanese Recent Past, Current & Future Analysis
for Imaging Agents by Product Segment - Contrast Media
(X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-32
Table 40: Japanese Long-term Projections for Imaging Agents
by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-32
Table 41: Japanese 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-33
4. Europe III-34
A.Market Analysis III-34
Outlook III-34
Trends III-34
Reimbursement III-34
Distribution Structure III-34
Direct Sales III-35
License Agreements III-35
Distribution Agreements III-35
A Price Sensitive Market III-35
Table 42: European Contrast Media Market (2005): Average
Cost of Contrast Media Per Imaging Procedure III-35
Table 43: Product Price of Select Contrast Agents in
Europe by Company III-36
Macro Market Environment III-36
Germany III-36
France III-37
United Kingdom III-37
Spain & Italy III-37
Scandinavia III-37
Strategic Corporate Developments III-38
Product Launch III-38
B.Market Analytics III-39
Table 44: European Recent Past, Current & Future Analysis
for Imaging Agents by Geographic Region - France, Germany,
UK, Italy, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-39
Table 45: European Long-term Projections for Imaging Agents
by Geographic Region - France, Germany, UK, Italy, Spain,
Russia and Rest of Europe Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-40
Table 46: European 10-Year Perspective for Imaging Agents by
Geographic Region - Percentage Breakdown of Dollar Sales for
France, Germany, UK, Italy, Spain, Russia and Rest of Europe
Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-41
Table 47: European Recent Past, Current & Future Analysis
for Imaging Agents by Product Segment- Contrast Media
(X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-42
Table 48: European Long-term Projections for Imaging Agents
by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-42
Table 49: European 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-43
4a. France III-44
A.Market Analysis III-44
Outlook III-44
Growth Stimulants III-44
Contrast Media III-44
Major Player III-44
Strategic Corporate Developments in the Recent Past III-45
B.Market Analytics III-45
Table 50: French Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment- Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radio-pharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-45
Table 51: French Long-term Projections for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-46
Table 52: French 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-47
4b. Germany III-48
A.Market Analysis III-48
Outlook III-48
Major Player III-48
Strategic Corporate Developments III-48
Product Launches III-50
B.Market Analytics III-51
Table 53: German Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment- Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-51
Table 54: German Long-term Projections for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-52
Table 55: German 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012
(includes corresponding Graph/Chart) III-52
4c. The United Kingdom III-53
A.Market Analysis III-53
Outlook III-53
Major Player III-53
Strategic Corporate Developments in the Recent Past III-53
B.Market Analytics III-55
Table 56: UK Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment- Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-55
Table 57: UK Long-term Projections for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-56
Table 58: UK 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-57
4d. Italy III-58
A.Market Analysis III-58
Outlook III-58
Major Player III-58
Strategic Corporate Developments III-58
B.Market Analytics III-60
Table 59: Italian Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment- Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-60
Table 60: Italian Long-term Projections for Imaging Agents
by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-61
Table 61: Italian 10-Year Perspective for Imaging Agents by
Product Segment-Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-62
4e. Spain III-63
Market Analysis III-63
Table 62: Spanish Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment- Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radio-pharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-63
Table 63: Spanish Long-term Projections for Imaging Agents
by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-64
Table 64: Spanish 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-65
4f. Russia III-66
Market Analysis III-66
Table 65: Russian Recent Past, Current & Future Analysis for
Imaging Agents by product Segment- Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-66
Table 66: Russian Long-term Projections for Imaging Agents
by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-67
Table 67: Russian 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-68
4g. Rest of Europe III-69
A.Market Analysis III-69
Outlook III-69
Strategic Corporate Developments III-69
B.Market Analytics III-69
Table 68: Rest of Europe Recent Past, Current & Future
Analysis for Imaging Agents by Product Segment-Contrast
Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) III-69
Table 69: Rest of Europe Long-term Projections for Imaging
Agents by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-70
Table 70: Rest of Europe 10-Year Perspective for Imaging
Agents by Product Segment- Percentage Breakdown of Dollar
Sales for Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) III-71
5. Asia-Pacific III-72
A.Market Analysis III-72
Outlook III-72
PET Imaging-An Overview III-72
ANSTO: Leading the Radiopharmaceuticals Market III-72
Strategic Corporate Developments III-72
Product Launch III-74
B.Market Analytics III-74
Table 71: Asia-Pacific Recent Past, Current & Future
Analysis for Imaging Agents by Product Segment - Contrast
Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-74
Table 72: Asia-Pacific Long-term Projections for Imaging
Agents by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-75
Table 73: Asia-Pacific 10-Year Perspective for Imaging
Agents by Product Segment- Percentage Breakdown of Dollar
Sales for Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) III-75
6. The Middle East III-76
Market Analysis III-76
Table 74: Middle East Recent Past, Current & Future Analysis
for Imaging Agents by Product Segment- Contrast Media
(X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) III-76
Table 75: Middle East Long-term Projections for Imaging
Agents by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-77
Table 76: Middle East 10-Year Perspective for Imaging Agents
by Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-78
7. Latin America III-79
Market Analysis III-79
Table 77: Latin American Recent Past, Current & Future
Analysis for Imaging Agents by Product Segment- Contrast
Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-79
Table 78: Latin America Long-term Projections for Imaging
Agents by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-80
Table 79: Latin American 10-Year Perspective for Imaging
Agents by Product Segment- Percentage Breakdown of Dollar
Sales for Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) III-81
IV. COMPETITIVE LANDSCAPE

To order this report:

World Imaging Agents (Contrast Media, Radiopharmaceuticals) Market http://www.reportlinker.com/p092557/World-Imaging-Agents-(Contrast-Media-Radiopharmaceuticals)-Market.html

More market research reports here!

Contacts:
Reportlinker.com
Nicolas
US: (805) 652-2626 or Int: +1-805-652-2626
Email: nbo@reportlinker.com

SOURCE: Reportlinker.com

mailto:nbo@reportlinker.com

http://www.reportlinker.com/p092557/World-Imaging-Agents-(Contrast-Media-Radiopharmaceuticals)-Market.html

This report analyzes the worldwide markets for Imaging Agents in Millions of US$. The major product segments analyzed are Contrast Media (X-Ray, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 67 companies including many key and niche players worldwide such as AMAG Pharmaceuticals Inc., Amersham Plc, Bayer Schering Pharma AG, Bayer HealthCare Pharmaceuticals, Bracco Group, E-Z-EM Inc., Covidien, Cytogen Corp., Daiichi Sankyo Company Limited, Eisai Co., Ltd, EPIX Pharmaceutical Inc., Guerbet Group, and Lantheus Medical Imaging. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

IMAGING AGENTS MCP-3336
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
A. Contrast Media I-3
X-Ray Contrast Media I-3
Magnetic Resonance Imaging (MRI) Contrast Media I-3
Ultrasound Contrast Media I-4
B. Diagnostic Radiopharmaceuticals I-4


II. EXECUTIVE SUMMARY

1. Industry Overview II-1
A Quick Primer On Imaging Agents II-1
Growth Drivers II-1
Growth Inhibitors II-2
Changing Dynamics of Imaging Agents II-2
Imaging Agents: Significant Growth Ahead II-3
Table 1: Worldwide Imaging Agents Market (2003): Percentage
Breakdown of Value Sales for Leading Imaging
Agents-Omnipaque, Cardiolite, Magnevist, Iopamiron,
Ultravist, Myoview, Visipaque, Omniscan, FDG and Others
(includes corresponding Graph/Chart) II-4
Rise of Non-Ionizing Imaging Techniques II-4
Table 2: Medical Diagnostic Procedures Conducted Worldwide
for the Year 2003: Breakdown by Imaging Modality Type -
X-ray/CT, MRI, Ultrasound and Radiopharmaceuticals (In
Millions) (includes corresponding Graph/Chart) II-5
Fusion Imaging Modalities: Greater Clinical Benefits II-5
Radiopharmaceuticals-An Exotic Tool II-5
Nanomaterials Taking the Center Stage II-6
Gadolinium Coated Nanoparticles- A Promising Imaging Agent II-6
A Peek Into the Pricing Dynamics II-6
A Synoptic Overview II-6
Pros & Cons II-7
Positive Factors Driving Prices II-7
Negative Factors Bearing Down on Prices II-7
Reimbursements II-8
"Under the Umbrella" II-8
Europe II-8
United States II-8

2. Market Trends & Issues II-10
Falling Prices Turn On the Heat II-10
X-Ray Contrast Media: Declining Sector II-10
MRI Contrast Media: Playing at Center Court II-10
Impact Wielded by Ballooning MRI Practices II-10
Ultrasound Contrast Media: A Rising Star in the Quadrant II-11
Fledging Market Battles Teething Challenges II-12
PET: A Prime Growth Driver for Radiopharmaceuticals II-12
Nuclear Medicine: A Potential Growth Avenue for
Radiopharmaceuticals II-13
Select Cardiology and Oncology Radiopharmaceuticals II-13

3. Competition II-14
Market Structure II-14
Key Market Metrics II-15
Big Guns in the Emerging MRI Market II-15
Bayer Schering Pharma AG: A Pioneering Developer of MRI
Contrast Agents II-15
Competitive Scenario - A Recent Past Perspective II-16
Table 3: Worldwide Imaging Agents Market (2004): Percentage
Breakdown of Value Sales for Leading Players- GE Healthcare,
Bracco, Tyco Healthcare/Mallinckrodt, Schering, BMS and
Others (includes corresponding Graph/Chart) II-16

Table 4: X-ray Medical Diagnostics Market Worldwide:
Percentage Market Share of Leading Players for the Years
2002, 2003, and 2004 - Amersham, Bracco, Tyco/ Mallinckrodt,
Inc, Schering, Guerbet and Others (Revenue Share) (includes
corresponding Graph/Chart) II-16

Table 5: MRI Diagnostics Market Worldwide: Percentage Share
of Leading Players for the Years 2003 and 2004 - Schering,
Amersham, Bracco, and Others (Revenue Share) (includes
corresponding Graph/Chart) II-17

Table 6: Radiopharmaceutical Medical Diagnostics Market
Worldwide: Percentage Market Share of Leading Players for the
Years 2003 and 2004 - Amersham, Bristol-Myers Squibb, Tyco/
Mallinckrodt, Inc and Others (Revenue Share) (includes
corresponding Graph/Chart) II-17

4. Technology Breakthroughs II-18
Molecular Imaging Agents: The Outer Limits II-18
On Cards: Hyperpolarized Gases as Contrast Agents II-18
Imaging Agents Make a Welcome Impact in the Field of
Alzheimer's Disease II-18
Technetium-99m: A Breakthrough Contrast Agent for CNS Imaging II-19
A New Imaging Agent for Radiopharmaceutical Scans II-19
Multi-Modal Image Registration: Combating Contrast Medium
Inconsistencies II-19
Saline Flushes To Help Ensure Accurate Delivery of Contrast
Agents II-20

5. Product Overview II-21
Contrast Agents II-21
Contrast Media: How Do They Function? II-21
Where Are They Used ? II-22
Evolution of Contrast Media: A Profile II-22
Bismuth Nitrate: Beginning of Contrast Agents II-22
Imaging Agents: Significant Developments in the Last Fifty Years II-23
Schering Develops First Intravenous Contrast Agent II-23
MRI: Creating a New Era for Contrast Agents II-23
A Peek into the Finer Points of Differences Among Contrast Media II-23
Viscosity II-23
Osmolality II-23
Chemotoxicity II-24
Second Generation Non-Ionic Contrast Agents: An Introduction II-24
Choice of the Contrast Medium: A Weighty Decision II-24
Factors affecting choice of Imaging Agents II-24
Taxonomy II-24
Types of Contrast Media II-24
X-Ray Contrast Medium II-25
First Generation High Osmolar Contrast Media II-25
Second Generation Low Osmolar Contrast Media or LOCM II-25
Table 7: Comparative Analysis of Structure of Non-ionic
and ionic X-ray Contrast Media II-26
MRI Contrast Medium II-26
Role of Contrast Enhancement in MR Angiography (MRA) II-27
MRI Contrast Agents for the Liver II-27
Paramagnetic extracellular contrast agents II-27
Hepatobiliary Gadolinium Chelates II-27
Superparamagnetic Iron Oxide Particles II-28
Ultrasound Contrast Medium II-28
Ultrasonographic Contrast Media: What Are They? II-28
Ultrasound Contrast Enhancement in Cardiology II-29
Functionalities of Vascular Ultrasound Contrast Agents II-29
Diagnostic Radiopharmaceuticals II-30
Key Radioactive Isotopes used as Diagnostic
Radiopharmaceuticals II-30
A Delineate of Diagnostic Radiopharmaceuticals II-31
Diagnostic Radiopharmaceuticals: A Technical Run-Through II-31
Applications II-32

6. A Segmental Review II-33
Contrast Media II-33
Popular Brands of Contrast Agents Available Worldwide II-33
A Peek into Select Imaging Agents Under Clinical Trials
Worldwide II-35
X-ray Contrast Media II-35
Market Scenario II-35
MRI Contrast Media II-36
Market Scenario II-36
Ultrasound Contrast Media II-36
Market Overview II-36
Competitive Scenario II-36
Diagnostic Radiopharmaceuticals II-36
Market Overview II-36
Immunoconjugates II-37
Market Overview II-37
Competitive Scenario II-37

7. Technology Dynamics II-38
Proprietary Technologies Making Significant In-Roads II-38
Advanced Magnetics' Proprietary Colloidal Superparamagnetic
Particle Technology II-38
Enzon's Single Chain Antigen-Binding Technology II-38
Immunomedics' Antibody Technology II-38
First Generation II-38
Second Generation II-38
Third Generation II-38
NeoRx's "Painting the Target" Technology II-39
Stage - I II-39
Stage - II II-39
Stage - III II-39
Gas Encapsulation Technology for Ultrasound Contrast Media II-39
Pharmacyclics' Texaphyrin Technology II-40
Regulatory Bodies II-40
Ultrasound Contrast Agents Are Drugs, Not Devices - Rules US FDA II-40
Entry Barriers II-40
Research Driven Markets II-40
Highly Competitive Market II-40
Economies of Scale II-41
Substitutes in Agents Manufacturing II-41
New X-ray Diagnostic Agents II-41
Amide-based Macrocyclic Ligands - Potential MRI Agents II-41
Gadolinium (III) Complexes - Potential MRI Contrast Agents II-41
Metal-Containing Compounds Act As Potential Contrast Agents II-41
Therapeutic Applications II-41
Diagnostic Applications II-41
Magnetic Gels as Potential MRI Contrast Agents II-42
PFCs as Diagnostic Contrast Agents II-42

8. Product Launches II-43
Bayer to Unleash Radiology Management System II-43
Bayer to Unveil Pre-Filled Contrast-Medium Cartridges for MRI II-43
Insight Agents to Launch Generic Contrast Media Solutions In
Europe II-43
Researchers Develop First Biocompatible MRI Contrast Agent II-43
Signalomics and Invitrogen Collaborate to Develop Nanocrystal
Reagents II-43
Schering AG Collaborates with Stanford University to Develop
Molecular Imaging Agent II-44
Schering and Avid to Develop Diagnostic Imaging Agents II-44
US National Institutes of Health Develops two PET Imaging Agents II-44
Bracco Diagnostics Canada Introduces MRI Contrast Agent
MultiHance II-44
JBCPL Launches Magnilek Contrast Agent II-44
Mallinckrodt Launches NeutroSpec(TM) II-44
Schering AG's Primovist(TM) Approved in Sweden II-45
Isovue - A Non-ionic Monomeric X-Ray Contrast Agent from
Bracco Diagnostics II-45
Schering Strengthens Position with MS-325 II-45
Berlex Launches MRI Contrast Agent II-45
Amersham Health Introduces Omnipaque II-45
Boston Scientific Corp Launches Galaxy System II-46
Syncor International Launches F-18 FDG II-46

9. Recent Industry Activity II-47
Bristol-Myers Squibb Medical Imaging Adopts New Identity,
Lantheus Medical Imaging II-47
Cytogen Corporation to Merge Business with EUSA Pharma Inc II-47
Bracco Group Acquires E-Z-EM II-47
EPIX Pharmaceuticals to Resubmit New Drug Application (NDA)
for Vasovist II-47
Bayer Schering, FutureChem Ink Licensing Deal II-47
NuView Radio Pharmaceuticals Inks Agreement for Non- Invasive
Imaging Agent II-48
Advanced Magnetics Inc Changes Name to AMAG Pharmaceuticals II-48
Bracco Diagnostics Inks Agreement with HealthTrust Purchasing
Group II-48
Bracco Diagnostics Offers MRI Products to HealthTrust
Purchasing Group II-48
Bayer HealthCare Offers MRI Contrast Agent to HealthTrust II-48
Bayer HealthCare Extends Contract with Premier II-48
Bayer HealthCare Sets Off US Operations II-49
Tyco Healthcare Renamed to Covidien Ltd II-49
Covidien Offers Imaging Solutions to MedAssets Supply Chain
Systems II-49
Siemens, M.D. Anderson Cancer Center Set up Research Centre II-49
Bayer, Berlex Merge Operations II-49
AION Diagnostics Forays Pre-Clinical Imaging Agent Market II-49
ART Acquires Alerion Biomedical II-50
EPIX to Merge with Predix II-50
Fujifilm Acquires Stake in Daiichi Radioisotope Laboratories II-50
Bracco Diagnostics Inks Agreement with Amerinet Vasovist
receives Green Signal in Australia II-50
AION Diagnostics Develops BioSilicon TM II-50
Sonazoid Receives Import Approval II-51
Schering AG Divests Radiopharmaceutical Business to Ion Beam
Applications and Institut National des Radioelements II-51
Vasovist Receives European Approval II-51
Albany Molecular Research Renews Supply Agreement with GE
Healthcare II-51
QuantRx Biomedical Corp. Acquires Stake in FluoroPharma II-51
Palatin Technologies Withdraws NeutroSpec Imaging Agent II-51
Diosynth Bags Contract to Produce Imaging Agent II-52
GE Healthcare Signs Marketing Agreement with PhotoCure II-52
DRAXIMAGE Receives the Green Signal in Europe II-52
Daiichi and Sankyo Sign a Merger Deal II-52
Bristol Myers and Imcor Pharmaceutical Forge Cross- Licensing
Agreement II-52
Kereos and Dow to Develop Unique Targeted Imaging Agents II-52
Bristol-Myers and Kereos to Collaborate on Molecular Imaging
Agents II-53
GE Acquires Amersham PLC II-53
Photogen Technologies Acquires Imagent(R) II-53
Dow and Kereos Collaborate II-53
IBC Pharmaceuticals and Schering AG Collaborate on Cancer
Research II-53
Schering Purchases CIS Bio International II-53
Imaging Diagnostic Systems to Collaborate with Schering II-54
Mallinckrodt Signs Distribution Agreement with Proxima
Therapeutics II-54
Immunomedics Signs Marketing Agreement with Teva-Tuteur II-54
DRAXIS Increases BrachySeed Production II-54
DRAXIMAGE Obtains FDA Approval for Manufacturing Lyophilized
Products II-55
Nycomed Amersham Acquires Bruker's TOMOJET II-55
DuPont Acquires Caribbean-PharmaLogic Radiopharmacies II-55
Bristol-Myers Squibb Company Acquires DuPont Pharmaceuticals II-55
Alliance Pharmaceutical Completes Acquisition of Molecular
Biosystems II-55
GE Medical Acquires Coincidence Technologies II-56
Tyco International Acquires Mallinckrodt II-56
Zydus Cadila Acquires 27.72 % Stake in German Remedies II-56
Schering Acquires Manufacturing Rights of MS-325 from EPIX
Medical II-56
Zydus Cadila Acquires Five Brands from Asta Medica II-56
AxCell BioSciences Forms Joint Venture with Institute for
Systems Biology II-56
Syncor Signs Purchasing Agreements with HSCA II-57
Syncor and InSource Health Services Sign Agreement II-57
DRAXIS Signs Agreement with BTG for INFECTON II-57
Peregrine Pharmaceuticals and Paul Scherrer Institute Expand
R&D Agreement II-57
Syncor and Broadlane Ink Agreement II-57
Syncor and Catholic Healthcare West Extend Agreement II-58
MedImmune and Targesome Sign R&D Agreement II-58
Vital Images Inks an Agreement with E-Z-EM Inc II-58
TriPath Imaging and MDS Ink Agreement II-58
North American Scientific Forges Strategic Relationship with
Certus International II-58
Mediaworks Launches RadiologyWeb II-59
Nycomed Amersham Extends Supply Contract with Novation II-59
Advanced Magnetics Receives Approval for Feridex II-59
Targesome Receives NCI Support for Developing Novel Diagnostic
Imaging Agents II-59
Bracco Acquires Product Lines and Intellectual Property of
Resolution Pharmaceuticals II-59
Guerbet Acquires Oxilan, an X-Ray Contrast Agent from Cook
Imaging II-60
Nycomed Amersham Imaging Associates with Global Healthcare
Exchange II-60
Nycomed Amersham and D-Pharm Ally to Develop New Imaging Agents II-60
Bracco Group Forges Strategic Alliance with Dyax Corp II-60
DRAXIS Signs Agreement with Cytogen Corp II-61
CV Therapeutics and Fujisawa Healthcare Sign Collaboration
Agreement II-61
Comprehensive Medical Imaging Signs Agreement with US Diagnostic II-61
Syncor International and GE Medical Systems Sign Strategic
Agreement II-61
Guilford Pharmaceuticals Licenses Dopascan to MAP Medical
Technologies II-62
Cytogen and Advanced Magnetics Sign Agreements II-62
Amersham Sells Nycomed Pharma Subsidiary II-62
Amersham Renames its Businesses II-62
Nycomed Amersham Obtains Approval from FDA for MYOVIEW II-62
Schering Obtains Approval for Cancer Imaging Agent II-62
Datscan Receives European Union Marketing Authorization II-63

10. Focus on Select Players II-64
AMAG Pharmaceuticals Inc (USA) II-64
Amersham Plc (UK) II-64
Bayer Schering Pharma AG (Germany) II-65
Bayer HealthCare Pharmaceuticals (US) II-65
Bracco Group (Italy) II-65
E-Z-EM Inc. (USA) II-66
Covidien (USA) II-66
Cytogen Corp. (USA) II-66
Daiichi Sankyo Company Limited (Japan) II-67
Eisai Co., Ltd (Japan) II-67
EPIX Pharmaceutical Inc. (USA) II-67
Guerbet Group (France) II-67
Lantheus Medical Imaging (USA) II-68

11. Global Market Perspective II-69
Table 8: World Recent Past, Current & Future Analysis for
Imaging Agents by Geographic Region- US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-69

Table 9: World Long-term Projections for Imaging Agents by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-70

Table 10: World 10-Year Perspective for Imaging Agents by
Geographic Region- Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Markets for Years 2003, 2008 &
2012 (includes corresponding Graph/Chart) II-71

Table 11: World Recent Past, Current & Future Analysis for
Contrast Media by Geographic Region- US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-72

Table 12: World Long-term Projections for Contrast Media by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-73

Table 13: World 10-Year Perspective for Contrast Media by
Geographic Region- Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Markets for Years 2003, 2008 &
2012 (includes corresponding Graph/Chart) II-74

Table 14: World Recent Past, Current & Future Analysis for
Contrast Media by Product Segment - X-Ray, MRI and Ultrasound
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-75

Table 15: World Long-term Projections for Contrast Media by
Product Segment - X-Ray, MRI and Ultrasound Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-75

Table 16: World 10-Year Perspective for Contrast Media by
Product Segment - Percentage Breakdown of Dollar Sales for
X-Ray, MRI and Ultrasound Markets for Years 2003, 2008 & 2012
(includes corresponding Graph/Chart) II-76

Table 17: World Recent Past, Current & Future Analysis for
X-Ray Contrast Media by Geographic Region- US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-77

Table 18: World Long-term Projections for X-Ray Contrast Media
by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-78

Table 19: World 10-Year Perspective for X-Ray Contrast Media
by Geographic Region- Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Markets for Years 2003, 2008 &
2012 (includes corresponding Graph/Chart) II-79

Table 20: World Recent Past, Current & Future Analysis for MRI
Contrast Media by Geographic Region- US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-80

Table 21: World Long-term Projections for MRI Contrast Media
by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-81

Table 22: World 10-Year Perspective for MRI Contrast Media by
Geographic Region- Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Markets for Years 2003, 2008 &
2012 (includes corresponding Graph/Chart) II-82

Table 23: World Recent Past, Current & Future Analysis for
Ultrasound Contrast Media by Geographic Region- US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Middle East and
Latin America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-83

Table 24: World Long-term Projections for Ultrasound Contrast
Media by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Middle East and Latin America
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-84

Table 25: World 10-Year Perspective for Ultrasound Contrast
Media by Geographic Region- Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Middle East and Latin America Markets for Years 2003,
2008 & 2012 (includes corresponding Graph/Chart) II-85

Table 26: World Recent Past, Current & Future Analysis for
Diagnostic Radiopharmaceuticals by Geographic Region- US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle
East and Latin America Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-86

Table 27: World Long-term Projections for Diagnostic
Radiopharmaceuticals by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-87

Table 28: World 10-Year Perspective for Diagnostic
Radiopharmaceuticals by Geographic Region- Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Middle East and Latin America
Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) II-88


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Outlook III-1
Growth Stimulants III-1
Medical Imaging: Changing the Healthcare Landscape III-1
Dynamics of Pricing III-1
Table 29: Hospital Purchases by GPOs in the United States -
Percentage Breakdown by Type for the Year 2002 (includes
corresponding Graph/Chart) III-2
Reimbursements Issues III-2
Medicare III-2
Magnetic Resonance Imaging III-3
Table 30: Medicare Reimbursements for Brain MRI Procedures
for the Year 2006 III-4

Table 31: Medicare Reimbursements for Breast MRI
Procedures for the Year 2006 III-5
Regulatory Environment III-5
Provisions Regarding Off-Label Usage of Contrast Media III-6
Contrast Media III-6
X-ray Contrast Media III-6
MRI Contrast Media III-7
Market Scenario III-7
Managed Care Vs MRI Technology Diffusion III-7
Ultrasound Contrast Media Market III-7
Diagnostic Radiopharmaceuticals III-7
Market Scenario III-7
Availability of Isotopes: A Tough Challenge III-7
Select Players III-8
Strategic Corporate Developments III-10
Product Launches III-20
B.Market Analytics III-22
Table 32: US Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment- Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-22

Table 33: US Long-term Projections for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-22

Table 34: US Historic Review for Imaging Agents by Product
Segment- Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
1995 through 1999 (includes corresponding Graph/Chart) III-23

Table 35: US 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-23

2. Canada III-24
A.Market Analysis III-24
Outlook III-24
Diagnostic Equipment Market III-24
LOCM Products Approved in Canada III-24
Select Player III-24
Strategic Corporate Developments III-25
B.Market Analytics III-27
Table 36: Canadian Recent Past, Current & Future Analysis
for Imaging Agents by Product Segment- Contrast Media
(X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) III-27

Table 37: Canadian Long-term Projections for Imaging Agents
by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-28

Table 38: Canadian 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-29

3. Japan III-30
A.Market Analysis III-30
Outlook III-30
Reimbursement Issues III-30
Select Players III-30
Strategic Corporate Developments III-31
B.Market Analytics III-32
Table 39: Japanese Recent Past, Current & Future Analysis
for Imaging Agents by Product Segment - Contrast Media
(X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-32

Table 40: Japanese Long-term Projections for Imaging Agents
by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-32

Table 41: Japanese 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-33

4. Europe III-34
A.Market Analysis III-34
Outlook III-34
Trends III-34
Reimbursement III-34
Distribution Structure III-34
Direct Sales III-35
License Agreements III-35
Distribution Agreements III-35
A Price Sensitive Market III-35
Table 42: European Contrast Media Market (2005): Average
Cost of Contrast Media Per Imaging Procedure III-35
Table 43: Product Price of Select Contrast Agents in
Europe by Company III-36
Macro Market Environment III-36
Germany III-36
France III-37
United Kingdom III-37
Spain & Italy III-37
Scandinavia III-37
Strategic Corporate Developments III-38
Product Launch III-38
B.Market Analytics III-39
Table 44: European Recent Past, Current & Future Analysis
for Imaging Agents by Geographic Region - France, Germany,
UK, Italy, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-39

Table 45: European Long-term Projections for Imaging Agents
by Geographic Region - France, Germany, UK, Italy, Spain,
Russia and Rest of Europe Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-40

Table 46: European 10-Year Perspective for Imaging Agents by
Geographic Region - Percentage Breakdown of Dollar Sales for
France, Germany, UK, Italy, Spain, Russia and Rest of Europe
Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-41

Table 47: European Recent Past, Current & Future Analysis
for Imaging Agents by Product Segment- Contrast Media
(X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-42

Table 48: European Long-term Projections for Imaging Agents
by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-42

Table 49: European 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-43

4a. France III-44
A.Market Analysis III-44
Outlook III-44
Growth Stimulants III-44
Contrast Media III-44
Major Player III-44
Strategic Corporate Developments in the Recent Past III-45
B.Market Analytics III-45
Table 50: French Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment- Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radio-pharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-45

Table 51: French Long-term Projections for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-46

Table 52: French 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-47

4b. Germany III-48
A.Market Analysis III-48
Outlook III-48
Major Player III-48
Strategic Corporate Developments III-48
Product Launches III-50
B.Market Analytics III-51
Table 53: German Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment- Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-51

Table 54: German Long-term Projections for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-52

Table 55: German 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012
(includes corresponding Graph/Chart) III-52

4c. The United Kingdom III-53
A.Market Analysis III-53
Outlook III-53
Major Player III-53
Strategic Corporate Developments in the Recent Past III-53
B.Market Analytics III-55
Table 56: UK Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment- Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-55

Table 57: UK Long-term Projections for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-56

Table 58: UK 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-57

4d. Italy III-58
A.Market Analysis III-58
Outlook III-58
Major Player III-58
Strategic Corporate Developments III-58
B.Market Analytics III-60
Table 59: Italian Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment- Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-60

Table 60: Italian Long-term Projections for Imaging Agents
by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-61

Table 61: Italian 10-Year Perspective for Imaging Agents by
Product Segment-Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-62

4e. Spain III-63
Market Analysis III-63
Table 62: Spanish Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment- Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radio-pharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-63

Table 63: Spanish Long-term Projections for Imaging Agents
by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-64

Table 64: Spanish 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-65

4f. Russia III-66
Market Analysis III-66
Table 65: Russian Recent Past, Current & Future Analysis for
Imaging Agents by product Segment- Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-66

Table 66: Russian Long-term Projections for Imaging Agents
by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-67

Table 67: Russian 10-Year Perspective for Imaging Agents by
Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-68

4g. Rest of Europe III-69
A.Market Analysis III-69
Outlook III-69
Strategic Corporate Developments III-69
B.Market Analytics III-69
Table 68: Rest of Europe Recent Past, Current & Future
Analysis for Imaging Agents by Product Segment-Contrast
Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) III-69

Table 69: Rest of Europe Long-term Projections for Imaging
Agents by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-70

Table 70: Rest of Europe 10-Year Perspective for Imaging
Agents by Product Segment- Percentage Breakdown of Dollar
Sales for Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) III-71

5. Asia-Pacific III-72
A.Market Analysis III-72
Outlook III-72
PET Imaging-An Overview III-72
ANSTO: Leading the Radiopharmaceuticals Market III-72
Strategic Corporate Developments III-72
Product Launch III-74
B.Market Analytics III-74
Table 71: Asia-Pacific Recent Past, Current & Future
Analysis for Imaging Agents by Product Segment - Contrast
Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-74

Table 72: Asia-Pacific Long-term Projections for Imaging
Agents by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-75

Table 73: Asia-Pacific 10-Year Perspective for Imaging
Agents by Product Segment- Percentage Breakdown of Dollar
Sales for Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) III-75

6. The Middle East III-76
Market Analysis III-76
Table 74: Middle East Recent Past, Current & Future Analysis
for Imaging Agents by Product Segment- Contrast Media
(X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) III-76

Table 75: Middle East Long-term Projections for Imaging
Agents by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-77

Table 76: Middle East 10-Year Perspective for Imaging Agents
by Product Segment- Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-78

7. Latin America III-79
Market Analysis III-79
Table 77: Latin American Recent Past, Current & Future
Analysis for Imaging Agents by Product Segment- Contrast
Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-79

Table 78: Latin America Long-term Projections for Imaging
Agents by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-80

Table 79: Latin American 10-Year Perspective for Imaging
Agents by Product Segment- Percentage Breakdown of Dollar
Sales for Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) III-81


IV. COMPETITIVE LANDSCAPE

To order this report:

World Imaging Agents (Contrast Media, Radiopharmaceuticals) Market

http://www.reportlinker.com/p092557/World-Imaging-Agents-(Contrast-Media-Radiopharmaceuticals)-Market.html

More market research reports here!

SOURCE: Reportlinker.com

Reportlinker.com
Nicolas
US: (805) 652-2626 or Int: +1-805-652-2626
Email: nbo@reportlinker.com